Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEFEND: Fesoterodine vs Desmopressin for Severe Nocturia in Elderly Women
NCT02262936Phase 3Terminated
- Sponsor
- Mount Sinai Hospital
- Start
- Jul 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fesoterodine in nocturia (2 arms), sponsored by Mount Sinai Hospital. Primary endpoint: Number of night time voids at 12 weeks. Started Jul 2015; status: terminated.
02
Drugs
fesoterodine
03
Conditions
nocturia
Beyond the preview
Go deeper on NCT02262936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02262936.